EECP for eczema and inflammatory skin disease
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a non-invasive treatment called enhanced external counter-pulsation (EECP) for people with atopic dermatitis or other inflammatory skin diseases that need wet-wrap therapy. EECP involves wearing cuffs on your legs that inflate and deflate to improve blood flow, and researchers want to see if it reduces skin inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have atopic dermatitis (eczema) or another red, itchy skin condition that needs wet-wrap therapy
- The affected area on your skin is more than 5% of your body (about the size of 5 of your palms)
- You weigh at least 40 kg (about 88 pounds) and are at least 150 cm (about 4 feet 11 inches) tall
- You are not pregnant or breastfeeding, and have not started taking new strong medications like steroids or biologics in the last 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.